STERIS plc stock (IE00BFY8C754): STE edges lower on NYSE as investors watch peer positioning

STERIS shares on the NYSE traded slightly lower around USD 211 in early June while market participants reassess the US infection-prevention specialist against key healthcare equipment peers.

STERIS stock on the New York Stock Exchange was recently quoted around USD 211 per share in early June, after closing at USD 211.07 on 06/01/2026, reflecting a modest day-on-day decline of about 0.8 percent compared with USD 212.73 in the prior session, according to price data from StockInvest as of 06/02/2026, underlining a relatively calm start to the month for the United States-listed healthcare equipment group.

The move comes as the Dublin-domiciled company, whose primary listing is on the NYSE under ticker STE, continues to trade with comparatively low beta of around 0.46 and a daily volatility near 1.7 percent, according to TradingView data for STERIS as of early June 2026, positioning it as a lower-volatility healthcare name within the broader US equity market.

On the fundamental side, STERIS most recently reported quarterly revenue of about USD 1.59 billion, essentially in line with an estimated USD 1.59 billion, while earnings per share reached roughly USD 2.83 in the latest reported period, according to Zacks Earnings Summary data dated 07/02/2025, which followed a prior quarter where EPS of USD 2.74 topped the consensus of USD 2.59.

At the same time, the company’s market capitalization stood near USD 24.2 billion in early June 2026 based on TradingView data, while CompaniesMarketCap, using an INR conversion, put the figure at about INR 1.957 trillion as of June 2026, highlighting the scale of STERIS among global healthcare equipment providers despite not being a member of the S&P 500.

Investor positioning also remains active: Sustainable Growth Advisers LP disclosed a holding valued at approximately USD 192.34 million in STERIS, according to a recent filing overview and news item dated 06/02/2026 on MarketBeat, signaling continued interest from institutional asset managers in the infection prevention specialist.

For investors based in the euro area, STERIS can also be accessed via German trading venues such as Tradegate, where the stock is typically quoted in EUR during European trading hours, though liquidity and spreads may differ from the primary NYSE line.

The stock traded at 211.07 USD on 06/01/2026 on the New York Stock Exchange, according to StockInvest as of 06/02/2026.

As of: 03/06/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: STERIS plc
• Sector/industry: Healthcare equipment and infection prevention solutions
• Headquarters/country: Dublin, Ireland / operational headquarters in the United States
• Core markets: North American and European hospitals, ambulatory surgery centers, pharmaceutical manufacturers and life science laboratories
• Key revenue drivers: Sterilization systems, surgical products, endoscope reprocessing, decontamination services and related consumables and services for healthcare and life science customers
• Home exchange/listing venue: New York Stock Exchange (STE)
• Trading currency: USD

STERIS plc: core business model

STERIS focuses on providing sterilization, decontamination and surgical infrastructure solutions, generating most of its revenue from equipment, consumables and service contracts that support infection prevention workflows in hospitals, procedure centers and life science facilities in North America and Europe.

STERIS plc in peer comparison

Against the broader healthcare equipment universe, STERIS is often assessed alongside US-listed peers such as Medtronic and Baxter International, which also supply critical hospital infrastructure and medical technology, even though their product mixes differ from STERIS’s emphasis on sterilization and infection prevention solutions.

TradingView data show that STERIS carries a beta of about 0.46 and daily volatility of around 1.7 percent as of early June 2026, compared with many large-cap medical technology stocks that frequently exhibit betas closer to 1.0, positioning the company at the lower end of the risk spectrum within its peer group from a share-price sensitivity standpoint.

Conclusion

The small early-June pullback in STERIS shares on the NYSE comes against a backdrop of steady fundamentals, including quarterly revenue of about USD 1.59 billion broadly in line with estimates and recent EPS prints that have hovered around the high USD 2 range.

In peer context, the stock’s comparatively low beta and focus on infection prevention and sterilization infrastructure differentiate it from broader medical technology names, which may influence how investors position STERIS within diversified healthcare portfolios.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.